Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 1

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 3(4)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05505734Phase 3Completed

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Role: lead

NCT03847896Phase 3Completed

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

Role: lead

NCT03769090Phase 3Completed

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

Role: lead

NCT04848662Phase 1Completed

To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.

Role: lead

NCT04234464Phase 3Completed

A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma

Role: lead

NCT03384745Phase 2Completed

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Role: lead

All 6 trials loaded